CALGARY, May 23, 2017 /PRNewswire/ - Oncolytics Biotech
Inc. (TSX:ONC) (OTCQX:ONCYF) (Oncolytics or the Company) today
announced that Dr. Andres A.
Gutierrez, Chief Medical Officer of Oncolytics Biotech Inc.
will present at the World Immunotherapy Congress USA 2017 in a session on Tuesday, May 23rd, 2017 at
3:20 pm PT. Dr. Gutierrez's
presentation will focus on the use of "REOLYSIN® as
potential novel immuno-oncology viral agent for the anti-cancer
armamentarium". The conference takes place on May 23rd and 24th at the Hilton San Diego Resort
and Spa in San Diego, CA.
"As the only company that has evaluated an
intravenously-administered oncolytic virus in hundreds of cancer
patients, Oncolytics is eager to share our experience with the
scientific and clinical communities to support the development of
oncolytic viruses for improved patient outcomes," said Dr.
Gutierrez. "Our presentation will demonstrate that REOLYSIN is a
true immuno-oncology agent that in addition to causing tumor cell
lysis, generates innate and adaptive anti-tumor immune responses.
We will address the debate surrounding different clinical endpoints
in immuno-oncology studies as we present our emerging safety and
positive efficacy data in combination with chemotherapy in breast
and pancreatic cancer trials. We are also excited to share our
plans for a registration study in metastatic breast cancer, and
discuss next generation trials of REOLYSIN in combination with
checkpoint inhibitors and IMID's."
More information regarding the presentation is available at:
http://www.terrapinn.com/conference/immunotherapy-congress-usa/2017-Agenda.stm
About the World Immunotherapy Congress USA
Following a successful launch in
Europe, World Immunotherapy
Congress has added a U.S. event. Co-located with Americas Antibody
Congress 2017, World Biosimilar Congress USA, and Cell Culture World Congress
USA. World Immunotherapy Congress
USA presents the unique
opportunity for pharma, biotech, government, academia, and their
partners to get the latest updates on both clinical and
pre-clinical developments in checkpoint inhibitors, cell therapy,
and oncolytic viral immunotherapy. It is where science meets
business to make immunotherapy the cornerstone of the fight against
cancer.
About Oncolytics Biotech Inc.
Oncolytics is a
biotechnology company developing REOLYSIN, an immuno-oncology
viral-agent, as a potential treatment for a variety of tumor types.
The compound induces selective tumor lysis and promotes an inflamed
tumor phenotype through innate and adaptive immune responses to
treat a variety of cancers. Oncolytics' clinical development
program emphasizes three pillars: chemotherapy combinations to
trigger selective tumor lysis; immuno-therapy combinations to
produce adaptive immune responses; and immune modulator (IMiD)
combinations to facilitate innate immune responses. Oncolytics
is currently planning its first registration study in breast
cancer, as well as studies in combination with checkpoint
inhibitors and IMID/targeted therapies in solid and hematological
malignancies. For further information about Oncolytics, please
visit: www.oncolyticsbiotech.com.
The session times are subject to change. This release and the
presentation related thereto contain forward-looking statements
which involve known and unknown risks, delays, uncertainties and
other factors not under the Company's control and which may cause
actual results, performance or achievements of the Company to be
materially different from the results, performance or expectations
implied by these forward-looking statements. Such risks and
uncertainties include, among others, the efficacy of
REOLYSIN® as a cancer treatment, the success and timely
completion of clinical studies and trials, uncertainties related to
the research and development of pharmaceuticals and uncertainties
related to the regulatory process. Investors should consult the
Company's quarterly and annual filings with the Canadian and U.S.
securities commissions for additional information on risks and
uncertainties relating to the forward-looking statements. Investors
are cautioned against placing undue reliance on forward-looking
statements. The Company does not undertake to update these
forward-looking statements, except as required by applicable
laws.
SOURCE Oncolytics Biotech Inc.